Sarecycline - NeuroDawn Pharmaceutical
Latest Information Update: 04 Aug 2023
Price :
$50 *
At a glance
- Originator NeuroDawn
- Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines; Vascular disorder therapies
- Mechanism of Action Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Stroke
Most Recent Events
- 04 Aug 2023 Chemical structure information added
- 08 May 2023 Preclinical trials in Stroke in China (PO)
- 08 May 2023 NeuroDawn Pharmaceutical plans the phase II ESPRIT trial in Stroke [PO,Tablet] in April 2023 (NCT05836753)